What is

AELMHU?

We are a non-profit association made up of pharmaceutical companies specializing in rare diseases that are firmly committed to discovering, researching, developing, and marketing innovative therapies that improve the lives of patients and their families.

Access reports

At AELMHU, we produce quarterly and annual reports on access to orphan drugs in Europe and Spain (
).

Check here for our latest update

NEWS

NEWS

AELMHU 15th anniversary web news

AELMHU celebrates 15 years of commitment to people with rare diseases

The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) celebrates its 15th anniversary today, a milestone that reaffirms the commitment of pharmaceutical companies dedicated to researching and developing treatments for ... Read more


FEDER and AELMHU renew their collaboration agreement


Annual Report on Access to Orphan Drugs in Spain 2025


Presentation of the Andalusian Plan for Rare Diseases


Report: ‘The social value of orphan drugs’


AELMHU within the Strategic Plan of the Pharmaceutical Industry


AELMHU at the PERTE for Vanguard Health

INTERVIEWS

ASSOCIATED COMPANIES

RESEARCH AND COMMITMENT to rare diseases

MEMBERS

Would you like to join AELMHU?

What is an orphan drug?

Orphan drugs (ODs) are innovative treatments, many of them biotechnological in origin, intended to diagnose, prevent, or treat patients with rare diseases for which there is no alternative therapy.

NEWSLETTER

Consent(Required)
(Required)
This field is a validation field and must remain unchanged.

  • AELMHU
  • C/ Paseo de la Castellana, 135 7th Floor 28046 Madrid
  • C/ Muntaner, 292, 1º 2ª
  • 08021 Barcelona

Subscribesubscribe to the

AELMHUNEWSLETTER

Consent(Required)
(Required)
This field is a validation field and must remain unchanged.

© 2021
Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (Spanish Association of Orphan and Ultra Orphan Drug Laboratories)